Fat loss Studies suggest that most weight lost with retatrutide comes from body fat rather than lean tissue, although preserving muscle mass still depends on: consuming adequate protein undertaking resistance exercise maintaining regular physical activity These remain important parts of any medically supervised weight management programme
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently without UK marketing authorisation from the MHRA or EMA
Balanced approach: BPC-157 + Ipamorelin combines one healing peptide with one GH secretagogue, addressing both concerns without complexity
A 2024 pilot study tracking 48 research subjects using tesofensine 0.5mg daily plus tirzepatide 5mg weekly found additive fat loss (tesofensine contributed central appetite suppression
In the era this article has been describing, where five distinct axes each have a leading molecule and the right answer for any given patient depends on which axis they actually need to optimize, the genetic question stops being interesting and starts being practical
None of these patients were diagnosed with dementia and were either taking GLP-1 or SGLT-2i